 Paper Publish Year,DOI,Carbohydrate/Protein Mimetic,Category ,Mimic of which Protein/Carbohydrate,Name of the Mimetic,Functions,Activity
2007,https://doi.org/10.2174/187152507781058663,Carbohydrate,Oligomers,heparin,SR123781A,as also proved to be promising,Venous thromboembolism (Phase III trials
2007,https://doi.org/10.1021/bc700212b,Carbohydrate,Liposome,sialyl Lewis X (sLeX),SuLea-PEG-DSPE,may be used as nanocarriers to target activated platelets for drug delivery to the injury sites of cardiovascular diseases,Cardiovascular Diseases:PEG-DSPE-based nanocarriers are employed in delivering drugs for thrombosis and cardiovascular conditions due to prolonged circulation times and reduced systemic toxicity
2007,https://doi.org/10.1021/bc700212b,Carbohydrate,Liposome,sialyl Lewis X (sLeX),SuLea-DSGA,Used as a glycolipid without a PEG spacer for initial targeting studies,Cardiovascular Diseases:PEG-DSPE-based nanocarriers are employed in delivering drugs for thrombosis and cardiovascular conditions due to prolonged circulation times and reduced systemic toxicity
2007,https://doi.org/10.1021/bc700212b,Carbohydrate,Liposome,sialyl Lewis X (sLeX),PEG-DSPE,"Prolongs circulation time, provides steric stability",Cardiovascular Diseases:PEG-DSPE-based nanocarriers are employed in delivering drugs for thrombosis and cardiovascular conditions due to prolonged circulation times and reduced systemic toxicity
2008,https://doi.org/10.1111/j.1747-0285.2008.00741.x,Carbohydrate,GAG Mimetics,heparan sulfate (HS),Idraparinux (SANORG 34006),"phase III clinical trials for the treatment of venous thromboembolism, anticogulant",Venous Thromboembolism (VTE):idraparinux is a synthetic pentasaccharide anticoagulant that inhibits Factor Xa. It was investigated for treating deep vein thrombosis (DVT) and pulmonary embolism (PE).
2008,https://doi.org/10.1111/j.1747-0285.2008.00741.x,Carbohydrate,GAG Mimetics,heparan sulfate (HS),synthetic hexadecasaccharide SR123781,Anticoagulant,Potent antithrombotic agent in venous and arterial thrombosis models
2008,https://doi.org/10.1111/j.1747-0285.2008.00741.x,Carbohydrate,GAG Mimetics,sulfated glycosaminoglycans (GAGs),Epicatechin Sulfate (ECS),Anticoagulant,"Cardiovascular Diseases:Reverses endothelial cell aging, improves nitric oxide production, and enhances vascular relaxation"
2009,https://doi.org/10.1002/chem.200900996,Carbohydrate,imino sugar derivative,amino sugar,"3,6-dihydro-2H-1,2-oxazines","Carbohydrate mimetics: 3,6-Dihydro-2H-1,2-oxazines mimic carbohydrates, interacting with carbohydrate-binding proteins.","Inhibit platelet aggregation, useful in cardiovascular diseases (e.g., thrombosis)"
2009,https://doi.org/10.1021/ja810025g,Protein,α-helix mimetic,MDM2 (Mouse Double Minute 2 homolog) in its interaction with p53 (Tumor Protein p53),H₂N-Phe-[Trp]-Leu-OH,"designed to inhibit the binding of MDM2 to p53, which is crucial for regulating the cell cycle and preventing tumor formation.","identified as a lead inhibitor with effective activity against MDM2/p53 binding, demonstrating a significant inhibitory effect (IC₅₀ < 50 μM)"
2009,https://doi.org/10.1161/ATVBAHA.109.187518,Protein,Peptide Mimetic,ApoA-I,2F,stability and lipid-binding properties were improved,mimicked many of the lipid binding properties of apoA-I but failed to alter lesions in a mouse model of atherosclerosis.
2009,https://doi.org/10.1161/ATVBAHA.109.187518,Protein,Peptide Mimetic,ApoA-I,4F,Inhibits inflammation and improves HDL properties,Administered as D-amino acid (D-4F) reduced atherosclerotic lesions in LDL receptor–null and apoE-null mice without altering plasma cholesterol levels. Improved anti-inflammatory properties in various conditions.
2009,https://doi.org/10.1161/ATVBAHA.109.187518,Protein,Peptide Mimetic,ApoA-I,5F,Protects against atherosclerosis,L-5F significantly protected mice from diet-induced atherosclerosis and improved HDL's anti-inflammatory properties.
2009,https://doi.org/10.1002/ejoc.200900599,Protein,N-methyl amino acids,"C-terminal region (Phe-Phe-Gly-Leu-Met),",H-Lys-Phe-Ile-Gly-LeuMet-NH2,Using this information the peptidomimetic H-Lys-(Me)- Phe-Ile-Gly-(Me)Leu-Met-NH2 was prepared,Screening of this series of five peptides on the depressor activity of rabbit blood revealed that the modification of Ile and Met lead to inactive compounds while the modification of Phe and Leu showed no effect.
2009,https://doi.org/10.1002/ejoc.200900599,Protein,N-methylated peptide,"C-terminal region (Phe-Phe-Gly-Leu-Met),",H-Lys-(Me)- Phe-Ile-Gly-(Me)Leu-Met-NH2,higher resistance against degradation.,full depressor activity
2009,https://doi.org/10.1080/15419060801891018,Protein,peptide,Connexin,Gap27,mimics Connexin,Inhibition of gap junction channel formation: Cx43 +
2010,https://doi.org/10.1517/17460441.2010.497811,Carbohydrate,Mixed-Type Oligosaccharides,glycosaminoglycan,idraparinux,"Idraparinux is a synthetic analog of the antithrombin-binding region of heparin, which is a critical site for heparin's anticoagulant activity.",Venous Thromboembolism (VTE):idraparinux is a synthetic pentasaccharide anticoagulant that inhibits Factor Xa. It was investigated for treating deep vein thrombosis (DVT) and pulmonary embolism (PE).
2010,https://doi.org/10.1517/17460441.2010.497811,Carbohydrate,Mixed-Type Oligosaccharides,glycosaminoglycan,arixtria,"Arixtra is a synthetic analog of the antithrombin-binding region of heparin, which is a critical site for heparin's anticoagulant activity.","Thromboembolic Disorders:Approved for preventing DVT post-surgery (hip/knee replacement) and treating acute DVT/PE. It blocks Factor Xa, reducing clot formation. Also used for unstable angina and myocardial infarction"
2010,https://doi.org/10.4155/fmc.10.259,Protein,Cyclic heptapeptide,barbourin,Integrilin® (eptifibatide),Antiplatelet agent,Prevents ischemic events
2011,https://doi.org/10.1016/j.bbamem.2011.03.016,Protein,Membrane protein mimetic,"Cytochrome P450, rhodopsin, voltage-sensing domain of KvAP",Nanodiscs,Reconstitute membrane proteins in a functional form within a stable and flat lipid bilayer,"Facilitate NMR studies of membrane proteins by providing a more native-like environment compared to micelles, with stable and tunable size for better structural and functional analysis."
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,Gi3α (C-terminal),TP10-Gi3α346–355,Activation of p42/p44 MAPK,Potential modulator of cell signaling in various diseases
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,Chromogranin A,Vasostatin-1,Anti-andrenergic,Potential cardiovascular applications
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,eNOS (Calmodulin-binding domain),Nosangiotide,Anti-angiogenic,Potential anti-cancer activity by inhibiting blood vessel formation
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,Calcitonin receptor,Camptide,cAMP modulation,Potential modulator of cAMP-dependent processes in various diseases
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,AT1AR receptor,AT1AR304–318 (M511),Blood vessel contraction,Potential modulator of blood pressure in cardiovascular diseases
2013,https://pubmed.ncbi.nlm.nih.gov/23378594/,Protein,Lyophilized peptide,apoA-I,D-4F,decreased inflammation in low-density lipoprotein receptor-null mice,"causes a reduction in metabolites of arachidonic and linoleic acids in the small intestine,Atherosclerosis"
2014,https://doi.org/10.1517/17425247.2014.902048,Carbohydrate,Glycopolymers,"Naturally occurring polysaccharides (e.g., glycosaminoglycans, chondroitin sulfate)",Glycopolymers,"Anticoagulant, anti-inflammatory, anti-tumor properties","Potential applications in treating cardiovascular diseases, inflammatory conditions, and cancer by mimicking biological activities of natural polysaccharides. May also be used as drug delivery systems and protein stabilizers in pharmaceutical formulations."
2014,https://doi.org/10.1021/bm500091e,Protein,Collagen mimetic peptide,Collagen,(Pro-Lys-Gly)4(Pro-Hyp-Gly)4(Asp-Hyp-Gly)4,"forms nanofibrous triple helices that entangle to form a hydrogel. adhere platelets, activate them (indicated by soluble P-selectin secretion), and clot plasma and blood similar to animal derived collagen and control surfaces. In addition to the thrombotic potential, THP-1 monocytes incubated with our KOD collagen mimetic showed minimal proinflammatory cytokine (TNF-α or IL-1β) production.","Promotes hemostasis by adhering and activating platelets, clotting plasma and blood similar to animal-derived collagen, while showing minimal proinflammatory cytokine production"
2015,https://doi.org/10.1016/j.biomaterials.2015.02.079,Protein,collagen mimetic,Collagen,Scl2,"Streptococcal collagen-like 2 protein with specific peptides to enhance its properties for use in hydrogels HAbind, CSbind and RGDS peptides were conjugated to acrylate-Scl2 via thiolacrylate chemistry","Potential for improved tissue engineering and regenerative medicine applications, particularly in cardiovascular and bone repair"
2015,https://doi.org/10.1159/000374044,Protein,antagonist,BDNF sequence,Betrofin3,inhibits brain derived neurotrophic factor (BDNF) peptide  that exerts the most striking pro-cardiomyogenic effect on ES cells,"enhances the differentiation of ES cell-derived cardiomyocytes and at least in part that a TrkB receptor blockade by K252a may negatively regulate the differentiation process of the ES cells into cardiomyocytes,potentially useful for cardiac regeneration."
2015,https://doi.org/10.1159/000374044,Protein,antagonist,FGF,FGLs,enhance EGFP expression,Potential for cardiac gene therapy monitoring through enhanced cardiac-specific EGFP expression
2015,https://doi.org/10.1159/000374044,Protein,antagonist,FGF,FGLL,enhance EGFP expression,Potential for cardiac gene therapy monitoring through enhanced cardiac-specific EGFP expression
2015,https://doi.org/10.1159/000374044,Protein,antagonist,NCAM (Neural Cell Adhesion Molecule),EnkaminE,enhance EGFP expression,"carries a cardiac-specific reporter transgene encoding EGFP in a concentration-and time-dependent manner,potentially useful for cardiac gene therapy monitoring"
2015,https://doi.org/10.1159/000374044,Protein,antagonist,NCAM (Neural Cell Adhesion Molecule),Plannexin,enhance EGFP expression,"carries a cardiac-specific reporter transgene encoding EGFP in a concentration-and time-dependent manner,potentially useful for cardiac gene therapy monitoring"
2016,https://doi.org/10.1016/j.drudis.2016.11.003,Protein,synthetic peptide,Disintegrin protein from snake venom,Eptifibatide,antiplatelet drug,"Inhibits glycoprotein IIb/IIIa, preventing platelet aggregation and blood clot formation, used in acute coronary syndromes"
2016,https://doi.org/10.1016/j.drudis.2016.11.003,Protein,antagonist,sarcosine,Saralasin,used to treat hyper tension,Angiotensin II receptor agonist to reduce hypertension
2016,https://doi.org/10.3389/fphar.2016.00526,Protein,Apolipoprotein mimetic peptides,apoA-I,18A,higher lipid affinity and enhanced anti-atherogenic properties,Potential therapeutic for reducing atherosclerosis and improving cholesterol transport
2016,https://doi.org/10.3389/fphar.2016.00526,Protein,Apolipoprotein mimetic peptides,apoA-I,5A,"Anti-inflammatory, antioxidant and atheroprotective effects","less toxic and more specific to the ATP-binding cassette transporter A1(ABCA1) in cholesterol transport,Atherosclerosis"
2016,https://doi.org/10.3389/fphar.2016.00526,Protein,Apolipoprotein mimetic peptides,apoA-I,ETC-642,induction of cholesterol and increase of HDL fraction,Potential treatment for atherosclerosis by reducing inflammation and increasing HDL
2016,https://doi.org/10.3389/fphar.2016.00526,Protein,Apolipoprotein mimetic peptides,apoA-I,FAMP,effectively enhance HDL biological function and it also has atheroprotective functions,Potential treatment for atherosclerosis by enhancing HDL function
2016,https://doi.org/10.3389/fphar.2016.00526,Protein,Apolipoprotein mimetic peptides,ApoE,ATI-5261,reduces aortic lesions and plaque formation,"induce ABCA1-mediated cholesterol transport and reduce aortic lesion area and plaque lipid content,dyslipidemia"
2016,https://doi.org/10.3389/fphar.2016.00526,Protein,Apolipoprotein mimetic peptides,ApoE,Ac-hE18A-NH2,reduces plasma cholesterol in several dyslipidemic animal models,Potential treatment for dyslipidemia by reducing plasma cholesterol
2017,https://doi.org/10.1002/ddr.21407,Protein,Collagen mimetic peptides,((ProLys-Gly)4(Pro-Hyp-Gly)4(Asp-Hyp-Gly)),KOD,Promotes haemostasis,Promotes hemostasis by replicating collagen's self-assembly
2017,https://doi.org/10.1002/ddr.21407,Protein,GPIIb/IIIa antagonist,RGD sequence,SC47643,Enhances stability of their agent against enzymatic degradation,Potential anti-thrombotic by inhibiting platelet aggregation
2017,https://doi.org/10.1002/ddr.21407,Protein,GPllb/llla antagonist,RGD sequence,FK633,Inhibits platelet aggregation,Inhibits platelet aggregation for potential thrombosis treatment
2017,https://doi.org/10.3390/ph10040078,Protein,methyl glycoside analogue,antithrombin III,Fondaparinux,prophylaxis and treatment of venous thromboembolism (VTE),Prevents and treats venous thromboembolism
2017,https://doi.org/10.3390/ph10040078,Protein,synthetic anticoagulant,Idrapainux,Idrabiotaparinux,effective and safe as the standard warfarin treatment for VTE,biotin segment of Idrabiotaparinux enables the neutralization of the drug using avidin as a neutralizing agent
2017,https://doi.org/10.3390/ph10040078,Protein,synthetic hexadecasaccharide,Heparin,SR123781,indirect antithrombin III dependent inhibitor of FXa,prolonged anti-FXa and antithrombin activity after intravenous and subcutaneous administration
2017,https://doi.org/10.3390/ph10040078,Protein,antithrombotic,Heparin,AV5026,dose-dependent antithrombic effect with similar activity,Highly selective depolymerization of heparin for antithrombotic activity
2017,https://doi.org/10.1007/978-1-4939-6857-2_1,Protein,anticalins,antibody,DigA16 (H86N),digoxin antidote,"dramatically decreases the free digoxin concentration in plasma and rapidly reducing its toxic effects,Digoxin antidote for treating digoxin toxicity"
2017,https://doi.org/10.1038/s41467-017-02008-y,Protein,adrenergic receptor,β44-m23,β1AR,ligand-induced variations in G-protein interaction underpin partial agonism,"Salbutamol-bound β1AR is more mobile than the other partial agonist-bound receptors but is still considerably more rigid than full agonist-bound receptor, Potential therapeutic target for adrenergic receptor-related diseases"
2020,https://doi.org/10.1038/s41598-020-63336-6,Protein,Therapeutic peptide,Connexin 43 (Cx43),Gap27,"Gap27 is designed to mimic the function of Cx43, which is crucial for intercellular communication in the heart. Cx43 plays a significant role in the conduction of electrical impulses between cardiomyocytes, which is essential for maintaining normal heart rhythm and function.","Gap27 has been shown to improve cardiac function and reduce arrhythmogenesis in heart failure models. Specifically, it decreases the progression of cardiac dysfunction, reduces the incidence and severity of arrhythmias, and mitigates cardiac hypertrophy and adverse remodeling in high-output heart failure conditions.The peptide works by potentially influencing the phosphorylation status of Cx43, particularly at the S368 site, which is associated with the lateralization of Cx43 in cardiomyocytes"